Stay updated with breaking news from Alpha Cognition. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alpha Cognition Inc. has announced positive results from a bioequivalence study with Alpha-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s disease. According to a release issued by Alpha, topline results confirmed that in healthy adult volunteers treated to steady state, Alpha-1062 was bioequivalent to galantamine
07.01.2022 - TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins ...
VANCOUVER, BC / ACCESSWIRE / December 7, 2021 / The Power Play by The Market Herald has announced the release of a new interview with Rover Metals, Swarmio Media, Nextech AR and Alpha Cognition discussing
Which biotech stocks on the CSE, TSXV and TSX have performed the best so far in 2021? Here's a look at the five top Canadian biotech stocks.
(1) Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - Alpha Cognition Inc. (TSXV: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce the appointment of Lauren D'Angelo to Chief Commercial Officer. In this role, she will ensure the integrated commercial success of the company. Her initial focus will be to establish the company's commercial strategy to effectively advance and position Alpha Cognition'...